Table 2.
Total N1 Cases/Controls | Cases n LGA/AGA | Controls n LGA/AGA | OR2 | 95% CI | |
---|---|---|---|---|---|
Overall | 7,292/12,406 | 988/5,670 | 1,398/9,779 | 1.21 | 1.11, 1.32 |
Excluding studies if <80% participants had LGA data3 | 6,542/11,294 | 874/5,088 | 1,247/8,933 | 1.22 | 1.11, 1.34 |
Excluding studies with hospital controls4 | 6,311/11,386 | 823/4,929 | 1,243/9,017 | 1.23 | 1.12, 1.36 |
Excluding studies with <300 cases5 | 7,000/11,902 | 939/5,443 | 1,327/9,393 | 1.22 | 1.11, 1.34 |
Birth weight <4,000g | 6,394/11,077 | 297/5,463 | 408/9,440 | 1.26 | 1.07, 1.48 |
Sex6 | |||||
Males | 4,106/6,905 | 552/3,192 | 782/5,435 | 1.18 | 1.05, 1.33 |
Females | 3,186/5,501 | 436/2,478 | 616/4,344 | 1.25 | 1.09, 1.43 |
Age at diagnosis7 | |||||
0-1 | 636/1,447 | 76/521 | 154/1,149 | 1.04 | 0.75, 1.44 |
>1-5 | 4,075/6,087 | 559/3,178 | 712/4,808 | 1.20 | 1.06, 1.35 |
>5 | 2,581/4,872 | 353/1,971 | 532/3,822 | 1.26 | 1.08, 1.46 |
Ethnicity8 | |||||
White/European/Caucasian | 6,042/10,858 | 812/4,747 | 1,232/8,618 | 1.18 | 1.07, 1.30 |
Other | 1,250/1548 | 176/923 | 166/1,161 | 1.44 | 1.14, 1.83 |
Immunophenotype | |||||
B-lineage cases | 5,735/12,406 | 771/4,456 | 1,398/9,779 | 1.20 | 1.09, 1.33 |
T-lineage cases | 705/12,406 | 105/546 | 1,398/9,779 | 1.32 | 1.05, 1.64 |
Total N includes those born SGA. Counts for cases and controls by LGA/AGA represent exposure of interest and reference group only.
ORs adjusted for child’s age group, sex, year of birth group, mother’s age group, parental education, ethnic Group, birth order group and study.
Greece, Australia
Greece, Brazil, France (Adele)
France (Adele), New Zealand
P-value of sex by LGA interaction term = 0.50
P-value of age by LGA interaction term = 0.66
P-value of ethnic group by LGA interaction term = 0.25